- Home
- MGNX vs ONL Comparison
MGNX vs ONL Comparison
Compare MGNX & ONL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MGNX
- ONL
- Stock Information
- Founded
- MGNX 2000
- ONL 2021
- Country
- MGNX United States
- ONL United States
- Employees
- MGNX N/A
- ONL N/A
- Industry
- MGNX Biotechnology: Pharmaceutical Preparations
- ONL Real Estate Investment Trusts
- Sector
- MGNX Health Care
- ONL Real Estate
- Exchange
- MGNX Nasdaq
- ONL Nasdaq
- Market Cap
- MGNX 257.3M
- ONL 210.4M
- IPO Year
- MGNX 2013
- ONL N/A
- Fundamental
- Price
- MGNX $3.23
- ONL $3.75
- Analyst Decision
- MGNX Hold
- ONL Hold
- Analyst Count
- MGNX 10
- ONL 1
- Target Price
- MGNX $7.17
- ONL N/A
- AVG Volume (30 Days)
- MGNX 465.7K
- ONL 353.0K
- Earning Date
- MGNX 11-05-2024
- ONL 02-25-2025
- Dividend Yield
- MGNX N/A
- ONL 10.72%
- EPS Growth
- MGNX N/A
- ONL N/A
- EPS
- MGNX N/A
- ONL N/A
- Revenue
- MGNX $141,329,000.00
- ONL $169,644,000.00
- Revenue This Year
- MGNX $174.73
- ONL N/A
- Revenue Next Year
- MGNX N/A
- ONL N/A
- P/E Ratio
- MGNX N/A
- ONL N/A
- Revenue Growth
- MGNX 16.68
- ONL N/A
- 52 Week Low
- MGNX $2.95
- ONL $3.01
- 52 Week High
- MGNX $21.88
- ONL $5.91
- Technical
- Relative Strength Index (RSI)
- MGNX 42.79
- ONL 38.01
- Support Level
- MGNX $3.10
- ONL $3.75
- Resistance Level
- MGNX $3.30
- ONL $3.91
- Average True Range (ATR)
- MGNX 0.19
- ONL 0.12
- MACD
- MGNX 0.00
- ONL -0.03
- Stochastic Oscillator
- MGNX 25.45
- ONL 6.52
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).
About ONL Orion Office REIT Inc.
Orion Office REIT Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.